image
Healthcare - Biotechnology - NASDAQ - NL
$ 16.8289
-3.43 %
$ 917 M
Market Cap
-4.98
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one PHVS stock under the worst case scenario is HIDDEN Compared to the current market price of 16.8 USD, Pharvaris N.V. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one PHVS stock under the base case scenario is HIDDEN Compared to the current market price of 16.8 USD, Pharvaris N.V. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one PHVS stock under the best case scenario is HIDDEN Compared to the current market price of 16.8 USD, Pharvaris N.V. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart PHVS

image
$20.0$20.0$19.0$19.0$18.0$18.0$17.0$17.0$16.0$16.0$15.0$15.0$14.0$14.0$13.0$13.0$12.0$12.0$11.0$11.015 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
0 REVENUE
0.00%
-96.9 M OPERATING INCOME
-11.73%
-132 M NET INCOME
-32.63%
-120 M OPERATING CASH FLOW
-29.10%
-538 K INVESTING CASH FLOW
-497.98%
2.68 M FINANCING CASH FLOW
-99.18%
0 REVENUE
0.00%
0 OPERATING INCOME
100.00%
-33.5 M NET INCOME
19.19%
-35 M OPERATING CASH FLOW
-5.09%
-161 K INVESTING CASH FLOW
47.47%
566 K FINANCING CASH FLOW
-42.92%
Balance Sheet Pharvaris N.V.
image
Current Assets 289 M
Cash & Short-Term Investments 281 M
Receivables 2.94 M
Other Current Assets 5.75 M
Non-Current Assets 1.96 M
Long-Term Investments 0
PP&E 1.48 M
Other Non-Current Assets 474 K
96.35 %Total Assets$291.4m
Current Liabilities 23 M
Accounts Payable 4.56 M
Short-Term Debt 222 K
Other Current Liabilities 18.2 M
Non-Current Liabilities 639 K
Long-Term Debt 639 K
Other Non-Current Liabilities 0
19.32 %77.03 %Total Liabilities$23.6m
EFFICIENCY
Earnings Waterfall Pharvaris N.V.
image
Revenue 0
Cost Of Revenue 252 K
Gross Profit -252 K
Operating Expenses 96.9 M
Operating Income -96.9 M
Other Expenses 35.5 M
Net Income -132 M
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)0(252k)(252k)(97m)(97m)(35m)(132m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
0.00% ROE
0.00%
0.00% ROA
0.00%
0.00% ROIC
0.00%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Pharvaris N.V.
image
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)20192019202020202021202120222022202320232024202420252025
Net Income -132 M
Depreciation & Amortization 270 K
Capital Expenditures -538 K
Stock-Based Compensation 16.2 M
Change in Working Capital 5.89 M
Others -4.18 M
Free Cash Flow -121 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Pharvaris N.V.
image
Wall Street analysts predict an average 1-year price target for PHVS of $34.3 , with forecasts ranging from a low of $22 to a high of $50 .
PHVS Lowest Price Target Wall Street Target
22 USD 30.73%
PHVS Average Price Target Wall Street Target
34.3 USD 104.01%
PHVS Highest Price Target Wall Street Target
50 USD 197.11%
Price
Max Price Target
Min Price Target
Average Price Target
505045454040353530302525202015151010Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 15
6. Ownership
Insider Ownership Pharvaris N.V.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema ZUG, Switzerland, June 02, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced a summary of data that were presented at the 14th C1-Inhibitor Deficiency and Angioedema Workshop. globenewswire.com - 2 weeks ago
Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses ZUG, Switzerland, May 19, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of abstracts for presentation at three upcoming congresses: the 14th C1-Inhibitor Deficiency and Angioedema Workshop, to be held from May 29-June 1, 2025, in Budapest; the 2025 Eastern Allergy Conference (EAC), to be held from May 29-June 1, 2025, in Palm Beach, Fl.; and the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, to be held from June 13-16, 2025, in Glasgow. globenewswire.com - 1 month ago
Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update ZUG, Switzerland, May 13, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced financial results for the first quarter ended March 31, 2025, and provided a business update. globenewswire.com - 1 month ago
Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4 Expansion of potential treatment applications of deucrictibant in people living with bradykinin-mediated angioedema Expansion of potential treatment applications of deucrictibant in people living with bradykinin-mediated angioedema globenewswire.com - 1 month ago
Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update ZUG, Switzerland, April 07, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update. globenewswire.com - 2 months ago
Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission ZUG, Switzerland, April 01, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that the European Commission (EC) has granted orphan designation to its investigational drug, deucrictibant, for the treatment of bradykinin-mediated angioedema. globenewswire.com - 2 months ago
Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress ZUG, Switzerland, March 03, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), highlighted safety and efficacy data of deucrictibant, which is currently being evaluated in two pivotal Phase 3 studies, following long-term dosing in the prophylactic and on-demand settings at the American Academy of Allergy, Asthma, & Immunology's Annual Scientific Meeting (AAAAI) and World Allergy Organization (WAO) Joint Congress, which was held from February 28–March 3, 2025, in San Diego, CA. globenewswire.com - 3 months ago
Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025 ZUG, Switzerland, March 03, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that its management will participate in the Leerink Partners Global Healthcare Conference 2025, taking place from March 10-12, 2025, at the W South Beach Hotel in Miami, FL. Details are as follows: globenewswire.com - 3 months ago
Pharvaris Outlines 2025 Strategic Priorities ZUG, Switzerland, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema (AAE), today outlined its strategic priorities for 2025. globenewswire.com - 5 months ago
Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates ZUG, Switzerland, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced financial results for the third quarter ended September 30, 2024, and highlighted recent business updates. globenewswire.com - 7 months ago
Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference ZUG, Switzerland, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced that its management will participate in the Inaugural Guggenheim Securities Healthcare Innovation Conference, taking place from November 11-13, 2024, at the InterContinental Boston. Details are as follows: globenewswire.com - 7 months ago
Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings ZUG, Switzerland, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks, today announced the acceptance of multiple abstracts at several upcoming scientific meetings. Presentation details are as follows: globenewswire.com - 8 months ago
8. Profile Summary

Pharvaris N.V. PHVS

image
COUNTRY NL
INDUSTRY Biotechnology
MARKET CAP $ 917 M
Dividend Yield 0.00%
Description Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
Contact J.H. Oortweg 21, Leiden, 2333 CH https://pharvaris.com
IPO Date Feb. 5, 2021
Employees 108
Officers Ms. Annick Deschoolmeester Chief Human Resources Officer Dr. Peng Lu M.D., Ph.D. Chief Medical Officer Mr. David W. Nassif J.D. Chief Financial Officer, Chief Legal Officer & Corporate Secretary Dr. Anne A. Lesage Ph.D. Chief Early Development Officer Maryann Cimino Director of Corporate Relations Mr. Wim Souverijns Ph.D. Chief Commercial Officer Dr. Stefan Abele Ph.D. Chief Technology Operations Officer Mr. Berndt Axel Edvard Modig CPA, M.B.A. Co-Founder, Chief Executive Officer & Executive Director Ms. Anna Nijdam M.Sc., R.A. Head of Strategic Finance & Principal Accounting Officer